INTIOTCPharmaceutical PreparationsFiscal year ends December 31

Inhibitor Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.11+0.00 (+0.09%)

Close on Oct 19, 2026

Market cap: $19.06M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Inhibitor Therapeutics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Inhibitor Therapeutics filed with the SEC

Apr 1, 2026, 8:00 AM ET
Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
Other events · EX-99.1 to Form 8-K
Dec 14, 2023, 6:02 AM ET
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
Material agreement · Other events · EX-99.1 to Form 8-K
Sep 15, 2022, 5:06 PM ET
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K